This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes
- 18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT
- Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial
- Functional Estrogen Receptor Imaging Before Neoadjuvant Therapy for Primary Breast Cancer
- 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications
- Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer
- Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation
- Pharmacodynamic Imaging Guides Dosing of a Selective Estrogen Receptor Degrader
- Assessment of Estrogen Receptor Expression in Epithelial Ovarian Cancer Patients Using 16{alpha}-18F-Fluoro-17{beta}-Estradiol PET/CT
- Feasibility and Predictability of Perioperative PET and Estrogen Receptor Ligand in Patients with Invasive Breast Cancer
- 18F-FES and 18F-FDG PET for Differential Diagnosis and Quantitative Evaluation of Mesenchymal Uterine Tumors: Correlation with Immunohistochemical Analysis
- Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer
- Oestrogen-related tumour phenotype: positron emission tomography characterisation with 18F-FDG and 18F-FES
- PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma
- 18F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical Analysis
- Imaging Tumor Phenotype: 1 Plus 1 Is More Than 2
- Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET
- The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions
- 7{alpha}-18F-Fluoromethyl-Dihydrotestosterone and 7{alpha}-18F-Fluoromethyl-Nortestosterone: Ligands to Determine the Role of Sex Hormone-Binding Globulin for Steroidal Radiopharmaceuticals
- Tumor Receptor Imaging
- Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol
- Biodistribution and Predictive Value of 18F-Fluorocyclophosphamide in Mice Bearing Human Breast Cancer Xenografts
- The Effects of Estrogen, Progesterone, and C-erbB-2 Receptor States on 18F-FDG Uptake of Primary Breast Cancer Lesions
- Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond
- Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer
- The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
- Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status
- Monitoring of Therapy in Androgen-Dependent Prostate Tumor Model by Measuring Tumor Proliferation
- In Vivo Prediction of Response to Antiestrogen Treatment in Estrogen Receptor-Positive Breast Cancer
- New Technologies in Breast Imaging
- [18F]Fluoroestradiol Radiation Dosimetry in Human PET Studies
- Glucose Metabolism of Breast Cancer Assessed by 18F-FDG PET: Histologic and Immunohistochemical Tissue Analysis